BioWorld

March 6, 2009

Proteon Snares $38M Round, and $550M Novartis Option

Proteon Therapeutics Inc. is banking on its lead product to clear a crucial Phase II study, the results of which could seal a $550 million deal with Novartis AG. (BioWorld Today) Read More

Optimer's Anti-Infective Pipeline Moving Ahead Via $33M Offering

Ortho Group Says Biologics Are no Longer 'Back in the Corner'

Obama Ties Health Reform To Prosperity of the U.S.

Isolagen Shares Jump 30% on Good Acne Trial Data

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...